Manufacturers of many types of patient-monitoring devices can add or improve remote-monitoring features without first getting regulatory clearance during the COVID-19 public health crisis, the US Food and Drug Administration said in an immediately-in-effect guidance document issued on 20 March.
The move is intended to help reduce the burden the novel coronavirus places on the health care system, the guidance explains
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?